Loading…
Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography
Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been documented. The aim of this...
Saved in:
Published in: | Cardiorenal medicine 2015-06, Vol.5 (3), p.199-207 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063 |
---|---|
cites | cdi_FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063 |
container_end_page | 207 |
container_issue | 3 |
container_start_page | 199 |
container_title | Cardiorenal medicine |
container_volume | 5 |
creator | Yılmaz, Mustafa Aydınalp, Alp Okyay, Kaan Tekin, Abdullah Bal, Uğur Abbas Bayraktar, Nilüfer Yıldırır, Aylin Müderrisoğlu, Haldun |
description | Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been documented. The aim of this study was to analyze and compare the effects of carvedilol and metoprolol on the development of CIN in patients undergoing coronary angiography. Methods: One hundred patients currently taking metoprolol and 100 patients currently taking carvedilol were enrolled into the study. Venous blood samples were obtained before and 48 h after contrast administration. Cystatin C and malondialdehyde values were examined and compared. CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl from the baseline value. Results: Seven patients in the carvedilol group (7%) and 22 patients in the metoprolol group (22%) developed CIN (p = 0.003). In the metoprolol group, the median cystatin C concentration increased significantly from 978 to 1,086 ng/ml (p = 0.001) 48 h after radiocontrast administration. In the carvedilol group, the median cystatin C concentration did not change significantly (1,143 vs. 1,068 ng/ml; p = 0.94). In the metoprolol group, the mean malondialdehyde concentration increased significantly from 7.09 ± 1.48 to 8.38 ± 2.6 nmol/l (p < 0.001). In the carvedilol group, the mean serum malondialdehyde concentration did not change significantly (7.44 ± 1.21 vs. 7.56 ± 1.11 nmol/l; p = 0.59). Conclusion: When compared to metoprolol, carvedilol might decrease oxidative stress and subsequent development of CIN. |
doi_str_mv | 10.1159/000381964 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000381964</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3741611051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063</originalsourceid><addsrcrecordid>eNptkc1r3DAQxUVoSUKaQ-4hCHJpD24lWZLlSyCYfgSStpT2LGRZ9jr1Ss7IXtj_vjK73bSlp5lhfrx5w0PogpK3lIryHSEkV7SU_AidUil5JgRhL_Z9rpg6QecxPiaMCElLIo7RCUuNKAt2inwV1qOBPgaPQ4srAxvX9EMYsPENfnBTGCEsYxsAfwW3cX7qfYer4CcwccrufDNb1-DPblxBGM202mLTTg4SAsEb2OJb3_WhAzOutq_Qy9YM0Z3v6xn68eH99-pTdv_l4111e59ZLtiUMSOplTVnnElmbUmlZVJK09bGGpvXXFlSt8vXTpiCKm6buuCqILlUwhKZn6Gbne4412vXWLe4HfQI_To50sH0-u-N71e6CxvNeaFyRpPA670AhKfZxUmv-2jdMBjvwhw1laUiea54kdDrf9DHMINP7y2UKEpZKJGoNzvKQogRXHswQ4legtSHIBN79af7A_k7tueTPw10Dg5A9e1hJ6HHpk3U5X-p_ZVfPFSu3A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1695796785</pqid></control><display><type>article</type><title>Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography</title><source>Open Access: PubMed Central</source><creator>Yılmaz, Mustafa ; Aydınalp, Alp ; Okyay, Kaan ; Tekin, Abdullah ; Bal, Uğur Abbas ; Bayraktar, Nilüfer ; Yıldırır, Aylin ; Müderrisoğlu, Haldun</creator><creatorcontrib>Yılmaz, Mustafa ; Aydınalp, Alp ; Okyay, Kaan ; Tekin, Abdullah ; Bal, Uğur Abbas ; Bayraktar, Nilüfer ; Yıldırır, Aylin ; Müderrisoğlu, Haldun</creatorcontrib><description>Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been documented. The aim of this study was to analyze and compare the effects of carvedilol and metoprolol on the development of CIN in patients undergoing coronary angiography. Methods: One hundred patients currently taking metoprolol and 100 patients currently taking carvedilol were enrolled into the study. Venous blood samples were obtained before and 48 h after contrast administration. Cystatin C and malondialdehyde values were examined and compared. CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl from the baseline value. Results: Seven patients in the carvedilol group (7%) and 22 patients in the metoprolol group (22%) developed CIN (p = 0.003). In the metoprolol group, the median cystatin C concentration increased significantly from 978 to 1,086 ng/ml (p = 0.001) 48 h after radiocontrast administration. In the carvedilol group, the median cystatin C concentration did not change significantly (1,143 vs. 1,068 ng/ml; p = 0.94). In the metoprolol group, the mean malondialdehyde concentration increased significantly from 7.09 ± 1.48 to 8.38 ± 2.6 nmol/l (p < 0.001). In the carvedilol group, the mean serum malondialdehyde concentration did not change significantly (7.44 ± 1.21 vs. 7.56 ± 1.11 nmol/l; p = 0.59). Conclusion: When compared to metoprolol, carvedilol might decrease oxidative stress and subsequent development of CIN.</description><identifier>ISSN: 1664-3828</identifier><identifier>EISSN: 1664-5502</identifier><identifier>DOI: 10.1159/000381964</identifier><identifier>PMID: 26195972</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Original Paper</subject><ispartof>Cardiorenal medicine, 2015-06, Vol.5 (3), p.199-207</ispartof><rights>2015 S. Karger AG, Basel</rights><rights>Copyright (c) 2015 S. Karger AG, Basel</rights><rights>Copyright © 2015 by S. Karger AG, Basel 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063</citedby><cites>FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478321/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478321/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26195972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yılmaz, Mustafa</creatorcontrib><creatorcontrib>Aydınalp, Alp</creatorcontrib><creatorcontrib>Okyay, Kaan</creatorcontrib><creatorcontrib>Tekin, Abdullah</creatorcontrib><creatorcontrib>Bal, Uğur Abbas</creatorcontrib><creatorcontrib>Bayraktar, Nilüfer</creatorcontrib><creatorcontrib>Yıldırır, Aylin</creatorcontrib><creatorcontrib>Müderrisoğlu, Haldun</creatorcontrib><title>Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography</title><title>Cardiorenal medicine</title><addtitle>Cardiorenal Med</addtitle><description>Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been documented. The aim of this study was to analyze and compare the effects of carvedilol and metoprolol on the development of CIN in patients undergoing coronary angiography. Methods: One hundred patients currently taking metoprolol and 100 patients currently taking carvedilol were enrolled into the study. Venous blood samples were obtained before and 48 h after contrast administration. Cystatin C and malondialdehyde values were examined and compared. CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl from the baseline value. Results: Seven patients in the carvedilol group (7%) and 22 patients in the metoprolol group (22%) developed CIN (p = 0.003). In the metoprolol group, the median cystatin C concentration increased significantly from 978 to 1,086 ng/ml (p = 0.001) 48 h after radiocontrast administration. In the carvedilol group, the median cystatin C concentration did not change significantly (1,143 vs. 1,068 ng/ml; p = 0.94). In the metoprolol group, the mean malondialdehyde concentration increased significantly from 7.09 ± 1.48 to 8.38 ± 2.6 nmol/l (p < 0.001). In the carvedilol group, the mean serum malondialdehyde concentration did not change significantly (7.44 ± 1.21 vs. 7.56 ± 1.11 nmol/l; p = 0.59). Conclusion: When compared to metoprolol, carvedilol might decrease oxidative stress and subsequent development of CIN.</description><subject>Original Paper</subject><issn>1664-3828</issn><issn>1664-5502</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNptkc1r3DAQxUVoSUKaQ-4hCHJpD24lWZLlSyCYfgSStpT2LGRZ9jr1Ss7IXtj_vjK73bSlp5lhfrx5w0PogpK3lIryHSEkV7SU_AidUil5JgRhL_Z9rpg6QecxPiaMCElLIo7RCUuNKAt2inwV1qOBPgaPQ4srAxvX9EMYsPENfnBTGCEsYxsAfwW3cX7qfYer4CcwccrufDNb1-DPblxBGM202mLTTg4SAsEb2OJb3_WhAzOutq_Qy9YM0Z3v6xn68eH99-pTdv_l4111e59ZLtiUMSOplTVnnElmbUmlZVJK09bGGpvXXFlSt8vXTpiCKm6buuCqILlUwhKZn6Gbne4412vXWLe4HfQI_To50sH0-u-N71e6CxvNeaFyRpPA670AhKfZxUmv-2jdMBjvwhw1laUiea54kdDrf9DHMINP7y2UKEpZKJGoNzvKQogRXHswQ4legtSHIBN79af7A_k7tueTPw10Dg5A9e1hJ6HHpk3U5X-p_ZVfPFSu3A</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Yılmaz, Mustafa</creator><creator>Aydınalp, Alp</creator><creator>Okyay, Kaan</creator><creator>Tekin, Abdullah</creator><creator>Bal, Uğur Abbas</creator><creator>Bayraktar, Nilüfer</creator><creator>Yıldırır, Aylin</creator><creator>Müderrisoğlu, Haldun</creator><general>S. Karger AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201506</creationdate><title>Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography</title><author>Yılmaz, Mustafa ; Aydınalp, Alp ; Okyay, Kaan ; Tekin, Abdullah ; Bal, Uğur Abbas ; Bayraktar, Nilüfer ; Yıldırır, Aylin ; Müderrisoğlu, Haldun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Original Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yılmaz, Mustafa</creatorcontrib><creatorcontrib>Aydınalp, Alp</creatorcontrib><creatorcontrib>Okyay, Kaan</creatorcontrib><creatorcontrib>Tekin, Abdullah</creatorcontrib><creatorcontrib>Bal, Uğur Abbas</creatorcontrib><creatorcontrib>Bayraktar, Nilüfer</creatorcontrib><creatorcontrib>Yıldırır, Aylin</creatorcontrib><creatorcontrib>Müderrisoğlu, Haldun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cardiorenal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yılmaz, Mustafa</au><au>Aydınalp, Alp</au><au>Okyay, Kaan</au><au>Tekin, Abdullah</au><au>Bal, Uğur Abbas</au><au>Bayraktar, Nilüfer</au><au>Yıldırır, Aylin</au><au>Müderrisoğlu, Haldun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography</atitle><jtitle>Cardiorenal medicine</jtitle><addtitle>Cardiorenal Med</addtitle><date>2015-06</date><risdate>2015</risdate><volume>5</volume><issue>3</issue><spage>199</spage><epage>207</epage><pages>199-207</pages><issn>1664-3828</issn><eissn>1664-5502</eissn><abstract>Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been documented. The aim of this study was to analyze and compare the effects of carvedilol and metoprolol on the development of CIN in patients undergoing coronary angiography. Methods: One hundred patients currently taking metoprolol and 100 patients currently taking carvedilol were enrolled into the study. Venous blood samples were obtained before and 48 h after contrast administration. Cystatin C and malondialdehyde values were examined and compared. CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl from the baseline value. Results: Seven patients in the carvedilol group (7%) and 22 patients in the metoprolol group (22%) developed CIN (p = 0.003). In the metoprolol group, the median cystatin C concentration increased significantly from 978 to 1,086 ng/ml (p = 0.001) 48 h after radiocontrast administration. In the carvedilol group, the median cystatin C concentration did not change significantly (1,143 vs. 1,068 ng/ml; p = 0.94). In the metoprolol group, the mean malondialdehyde concentration increased significantly from 7.09 ± 1.48 to 8.38 ± 2.6 nmol/l (p < 0.001). In the carvedilol group, the mean serum malondialdehyde concentration did not change significantly (7.44 ± 1.21 vs. 7.56 ± 1.11 nmol/l; p = 0.59). Conclusion: When compared to metoprolol, carvedilol might decrease oxidative stress and subsequent development of CIN.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>26195972</pmid><doi>10.1159/000381964</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1664-3828 |
ispartof | Cardiorenal medicine, 2015-06, Vol.5 (3), p.199-207 |
issn | 1664-3828 1664-5502 |
language | eng |
recordid | cdi_crossref_primary_10_1159_000381964 |
source | Open Access: PubMed Central |
subjects | Original Paper |
title | Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A50%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Carvedilol%20and%20Metoprolol%20for%20Preventing%20Contrast-Induced%20Nephropathy%20after%20Coronary%20Angiography&rft.jtitle=Cardiorenal%20medicine&rft.au=Y%C4%B1lmaz,%20Mustafa&rft.date=2015-06&rft.volume=5&rft.issue=3&rft.spage=199&rft.epage=207&rft.pages=199-207&rft.issn=1664-3828&rft.eissn=1664-5502&rft_id=info:doi/10.1159/000381964&rft_dat=%3Cproquest_cross%3E3741611051%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1695796785&rft_id=info:pmid/26195972&rfr_iscdi=true |